- Home
- NA vs BMEA Comparison
NA vs BMEA Comparison
Compare NA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- BMEA
- Stock Information
- Founded
- NA 2019
- BMEA 2017
- Country
- NA China
- BMEA United States
- Employees
- NA N/A
- BMEA N/A
- Industry
- NA Semiconductors
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NA Technology
- BMEA Health Care
- Exchange
- NA Nasdaq
- BMEA Nasdaq
- Market Cap
- NA 108.7M
- BMEA 96.9M
- IPO Year
- NA 2022
- BMEA 2021
- Fundamental
- Price
- NA $4.20
- BMEA $1.01
- Analyst Decision
- NA
- BMEA Strong Buy
- Analyst Count
- NA 0
- BMEA 7
- Target Price
- NA N/A
- BMEA $8.71
- AVG Volume (30 Days)
- NA 99.9K
- BMEA 1.2M
- Earning Date
- NA 08-15-2025
- BMEA 11-04-2025
- Dividend Yield
- NA N/A
- BMEA N/A
- EPS Growth
- NA N/A
- BMEA N/A
- EPS
- NA N/A
- BMEA N/A
- Revenue
- NA $3,369,693.00
- BMEA N/A
- Revenue This Year
- NA N/A
- BMEA N/A
- Revenue Next Year
- NA N/A
- BMEA N/A
- P/E Ratio
- NA N/A
- BMEA N/A
- Revenue Growth
- NA N/A
- BMEA N/A
- 52 Week Low
- NA $3.33
- BMEA $0.87
- 52 Week High
- NA $31.48
- BMEA $7.50
- Technical
- Relative Strength Index (RSI)
- NA 40.50
- BMEA 30.44
- Support Level
- NA $4.14
- BMEA $0.87
- Resistance Level
- NA $5.15
- BMEA $1.42
- Average True Range (ATR)
- NA 0.36
- BMEA 0.09
- MACD
- NA 0.01
- BMEA -0.02
- Stochastic Oscillator
- NA 11.82
- BMEA 25.20
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.